Several studies have indicated that the upregulation of CD44 in many cancer types, including prostate, ovarian, and brain cancer, is correlated with aggressive biological behavior and poor prognosis (Hassn Mesrati et al., 2021). This evidence concerns the gene CD44 and cancer.